PureTech Appoints Joseph Bolen as CSO
20 October 2016
PureTech Health plc
PureTech Appoints Industry Leader Joseph Bolen as Chief Scientific Officer
PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary biotech company developing 21st century medicines, today announced the appointment of Joseph Bolen, Ph.D., as the Company's Chief Scientific Officer. In this new role, Dr. Bolen will lead the scientific development and advancement of PureTech's pipeline and will work closely with the team and Scientific Advisory Board as the Company identifies and pursues new modalities to address significant medical needs.
"We are tremendously excited to bring Joe's visionary leadership and drug development expertise to PureTech," said Daphne Zohar, Chief Executive Officer of PureTech Health. "Joe is a seasoned industry expert who brings the ideal balance of rigor and creativity to the role of CSO, and shares our vision for identifying and nurturing innovation that can potentially redefine healthcare."
Joseph Bolen brings to PureTech decades of industry experience in immunology and oncology, having overseen the discovery and advancement of more than 30 drugs into clinical development including Velcade®, Entyvio® and Ninlaro®. Dr. Bolen most recently oversaw all aspects of research and development for Moderna Therapeutics as President and Chief Scientific Officer. Previously, he was Chief Scientific Officer and Global Head of Oncology Research at Millennium: The Takeda Oncology Company. Prior to joining Millennium in 1999, Dr. Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough (DNAX), and Bristol-Myers Squibb. He began his career at the NIH, where he contributed to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system. Dr. Bolen graduated from the University of Nebraska with a B.S. degree in Microbiology & Chemistry and a Ph.D. in Immunology and conducted his postdoctoral training in Molecular Virology at the Kansas State University Cancer Center.
"PureTech Health is one of the most exciting companies in biotech, advancing truly unique multi-modal solutions to some of today's most significant healthcare challenges through modulation of the human nervous and immune adaptive systems," Dr. Bolen said. "I look forward to working closely with the highly accomplished PureTech team, the world-class Scientific Advisory Board, and the vast PureTech network of colleagues across the world who believe that we are entering into a new era of technology and science convergence that will profoundly impact our understanding of disease and fundamentally change the practice of medicine. Our mission at PureTech Health is to collaborate broadly with biomedical science and technology leaders in order to generate the most exciting ideas and then to transform these concepts into breakthrough medicines."
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biotech company creating 21st century medicines that modulate the adaptive human systems. Our therapies target the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease across multiple dimensions rather than through a single receptor or pathway. We are advancing more than 20 clinical studies across our pipeline, with five human proof-of-concept studies and multiple pivotal or registration studies expected to read out in the next two years. PureTech Health's pipeline is sourced and filtered by the world's leading scientific experts, who along with PureTech's leading team and board analyse more than 650 scientific discoveries per year to identify the most promising opportunities for patients. This process places the PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter.
Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward- looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward- looking statements, whether as a result of new information, future events or otherwise.
# # #
For further information, please contact:
|
PureTech |
+1 617 651 3156 |
|
Allison Mead, Director, Communications and Investor Relations |
|
|
|
|
|
FTI Consulting (Communications adviser to PureTech) |
+44 (0) 20 3727 1000 |
|
Ben Atwell Matthew Cole |
|
This information is provided by RNS
Latest directors dealings
- 2 days ago Savannah Energy
- 2 days ago Buccaneer Energy PLC
- 2 days ago Savannah Energy
- 2 days ago Carclo
- 2 days ago Schroder Japan Growth Fund